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Poly(a-L-glutamic acid) (PGA) was grafted with amino acid and ofigopeptide spacers 
up to 5 amino acids with the use of ~,~I-~arbony~diimidazo~e and 2~3-dihydro-1,2-bent- 
isoth~azole-3~n-l~l-dioxide (saecharin~ as an additive, and these polypeptides were charac- 
terized. The antitumor antibiotic adriamycin was covalently coupled via an amide bond 
onto PGA and onto the grafted polymers with the use of N-ethoxycarbonyl-2-ethoxy- 
1,2-dihydroquinoline (EEDQ); these conjugates were characterized. The conjugates con- 
taining Gly-Gly--L-Leu spacer arms did yield free adriamycin upon digestion with papain. 
Adriamy~in gave fairly stable complexes with PGA-~driamy~in and branched po~ypeptide- 
adriamycin conjugates; these complexes were characterized. 
INTRODUCTION 
Major problems in the administration of 
cytostatic agents are the lack of specificity 
of the drug for the tumor cell, the toxic 
side effects and the development of resistence 
of tumors for a particular drug. Extracel- 
lular polymeric release systems can be ap- 
plied to maintain constant levels of the 
drug in a particular body compartment 
for extended periods of time. Examples of 
these systems are the well known DNA. 
anthracycline complexes developed by Trouet 
et al. [ 11. The release of the drug from 
these systems is at least partially governed 
by the clearance of plasma from the free 
drug, which in turn leads to further dis- 
sociation of the DNA complexes. In principle, 
constant levels of the drug can also be ob- 
tained by bioerosion of degradable polymer 
matrices or by extracellular cleavage of 
covalently bound polymer-drug conjugates. 
Although peak concentrations of the drug 
can be avoided using these systems and a 
decrease in systemic toxicity can be ex- 
pected, a more selective administration of 
the drug would be advantageous. This could 
be achieved with the use of endocellular 
release systems, which release the drug after 
being incorporated by tumor cells. Only 
after uptake by tumor cells should the con- 
jugates degrade and release the parent drug. 
Tumor cells show a higher degree of up- 
take of macromolecules by endocytosis 
than their normal counterp~ts do. After 
internalization of the polymer-drug con- 
jugate, a phagosome is formed which fuses 
with a lysosome, and subsequently the 
polymer-drug conjugate is exposed to a 
mixture of at least 40 digestive enzymes 
at an acidic pH (4- 5). 
Information on the presence and activity 
of specific enzymes in the lysosomal com- 
partments can be used to design polymer- 
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drug conjugates in which the drug is coupled 
to the macromolecular carrier through spacers 
which can be easily cleaved by the enzymes 
involved [ 21. Macromolecular prodrugs can 
be designed which, by virtue of the presence 
of high levels of specific enzymes at the 
tumor cell membrane (y-glutamyl transferase) 
[3] or near the tumor (plasmin), rapidly 
release the drug at the membrane or in the 
immediate surroundings of the tumor [4]. 
Problems which still exist are the competi- 
tive uptake of macromolecular prodrugs by 
endocytosing cells, e.g. RES, which in princi- 
ple can be avoided by the coupling of ap- 
propriate antibodies against the tumor cells 
onto the polymer-drug conjugate. In this 
paper we have concentrated on the develop- 
ment of high molecular weight prodrugs of 
adriamyc~ using polyps-L-glutami~ acid) 
as a biodegradable carrier and different 
peptides as spacers. These systems were 
characterized with respect to composition 
and load of adriamycin by spectroscopic 
and chemical methods. 
RESULTS AND DISCUSSION 
a. Prodrug design 
Polymeric systems of anthracyclines which 
have been investigated include: DNA (adria- 
mycin [5] and daunomycin [l] ); antibodies 
and fab dimers (daunomycin [6-S] and 
adriamycin 191); bovine serum albumin 
(daunorubicin [lo] ) and various other 
proteins (daunorubicin [ 111); poly(D-lysine) 
(daunomycin [9] ); polyglutamic acid (adria- 
mycin salt [ 121); poly(~~-hydroxypropyl- 
L-glutamine) (adri~ycin hydrazone [13 3 ); 
polyasp~ic acid (dauno~bicin [ 141); lectins 
(daunomycin ] 151); dextran (dauno~bi~in 
[ 13, 163 ); polyglutaraldehyde (adriamycin 
[12]) and a copolymer of 2-(hydroxy)ethyl 
methacrylate and vinylpyrrolidone (dauno- 
rubicin [ 171). 
Polyglutamic acid (PGA) and derivatives 
have also been used as carriers for mustard 
compounds [ 181, cyclophosphamide [ 191, 
Ara-C [ 201 and steroid hormones [21- 
251. Poly(a-amino acids) were also used as 
biodegradable matrices for the release of 
bioactive compounds [26-281. PGA pos- 
sesses factor VIII-like coagulant activity 
[29] and PGA has been tested as a plasma 
expander [30]. Adriamycin yields a water- 
insoluble salt with PGA which showed anti- 
tumor activity and greatly reduced toxicity 
in mouse mammary experiments [ 121. 
We have concentrated on the use of PGA 
as a carrier, because this polymer can be 
readily degraded by lysosomal enzymes, 
is rather plasma stable and contains sufficient 
reactive groups for derivatization. After 
partial derivatization the conjugate will 
still be water-soluble owing to residual car- 
boxylate groups. PGA is not expected to 
be toxic in the quantities required for the 
use as a carrier and can be readily obtained 
with different molecular weight distribu- 
tions. 
The interpolation of appropriate spacers 
between carrier and the bioactive compound 
to meet optimal requirements for lysosomal 
attack and release of the drug has been 
applied by several investigators [2, 10, 311. 
Thus, Trouet et al. [lo] have shown that 
optimal spacers consisted of tri- and tetra-L- 
Leu-terminal peptides attached to succinylat- 
ed e-lysine groups of albumin. Kopecek [2] 
described the peptide-spacer dependent re- 
lease of p-nitroaniline from N-( 2-hydroxy- 
propyl)methacrylamide using thiolproteinases 
(Cathepsin B, L and H) as important repre- 
sentatives of the lysosomal enzyme popula- 
tion Because both the length and the com- 
position of the spacer are of great importance 
we have synthesized and characterized a 
number of conjugates with various spacer 
arms (l-5 amino acid residues). Tyrosine 
was incorporated in two of the systems to 
enable labeling with radioactive tracers 
which should aid in the study of biodegrada- 
tion of the conjugate (Table 2). 
Adriamycin displays a tendency to self- 
association in aqueous solution, resulting 
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in dimers, and even higher oligomers [32, 
331 due to the hydroquinone-quinone 
like structure in the aglycon. It can be ex- 
pected that free adriamycin might yield 
relatively strong charge transfer complexes 
with the covalently bound drug in the con- 
jugates. The application of a negatively 
charged carrier such as PGA might greatly 
add to the stability of these complexes. 
b. Synthesis and characterization 
Polyglutamic acid (PGA) was prepared 
according to Blout et al. [34-361 (Scheme 
1) by triethylamine-initiated polymerization 
of L-glutamic acid 4-benzyl ester [37] N- 
carboxyanhydride [38] in toluene and 
subsequent debenzylation of the polymers 
obtained with the use of hydrogen bromide 
(Scheme 1). Molecular weights (a”) of the 
polymers typically ranged from 50,000 
- 
_J 
"aH - 
_) 
"a 
Poly glutamc ac,d 
b 0 
poly #-benzyl glutamate 
Scheme 1. Synthesis of poly(a-L-glutamic) acid. 
up to 350,000 daltons. Residual benzyl 
groups mounted up to 5% (UV spectrometry) 
(Table 1). Both variables (ii;r, and residual 
groups) largely depend on the conditions 
employed during the debenzylation proce- 
dure. The material obtained as described 
(experimental, Table 1) was free of microgel 
particles and readily dissolved in dimethyl- 
formamide. 
In our efforts to attach adriamycin direct- 
ly onto PGA we found that the majority 
of the well established techniques used in 
peptide synthesis were not suitable or gave 
erratic results due to the nature of both the 
carboxylic component (PGA) and the amine 
(adriamycin). First, activation of PGA with 
carbodiimides [ 39, 401 or Woodward reagent 
K [41] also gave rise to the incorporation 
of N-acylisourea derivatives, which do not 
further react with nucleophiles. Secondly, 
it has been shown [42, 431 that overactiva- 
tion of lateral carboxylic groups in glutamic 
and aspartic acid containing peptides may 
result in the formation of cyclic imides, 
which, in turn, are likely to isomerise into 
the corresponding o-peptides or even may 
result in chain scission. The latter fragmenta- 
tion became a serious side reaction with 
the use of N,N’-carbonyl diimidazole (CDI) 
[44]. Thus, addition of CD1 to a stirred 
TABLE I 
Molecular weight, &iv, and residual benzyl groups 
of poly(a-L-glutamic acid) (PGA) 
Batch ii;i,a Residual benzyl groupsb 
(mol %) 
PGA, 1.3 x lo5 5 
PGA, 3.0 x lo4 <0.5 
PGA, 2.5 x 10’ <0.5 
PGA,C 3.5 x los 2.5 
aDetermined by viscometry using the relation [q ] = 
3.13 X 10’ (ii;iy)0.965 [50-521. 
bDetermined by UV spectrometry using r-benzyl- 
L-glutamate as a reference compound. 
‘Deprotection was accomplished by transfer hydro- 
genation of poly-y-L-benzylglutamate [53]. 
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solution of PGA in dimethylformamide 
resulted in a rapid decrease in viscosity 
and poor recoveries of PGA after dialysis. 
Moreover, in view of the polyfunctionality 
of adriamycin (amine, ketone, quinone, 
hydroquinone, phenolic OH, primary, sec- 
ondary and tertiary OH and the sensitive 
2deoxyglycoside acetal) the conditions of 
coupling of the drug onto the polymer 
must be compatible with the structure ele- 
ments present. This implies that the great 
majority of methods for the establishment 
of covalent bonds, including those based 
on oxidation-reduction reactions [45], is 
not suitable and lays a number of restric- 
tions during coupling and work-up of prod- 
ucts. Selective coupling of the amino group 
in the daunosamine moiety without con- 
comitant formation of esters also greatly 
A’-Ethorycarbonyl-2- 
-cthoxy-1,2-dlhydro- 
quinolinc (EEDQ) 
- EtOH -co2 I 
il 
mixed carbonic 
anhydride 
Scheme 2. Direct conjugation of adriamycin onto 
PGA via an amide bond using EEDQ. 
reduces the number of methods available. 
We have found that the use of N-ethoxy- 
carbonyl-2-ethoxy-1,2-dihydroquinoline 
(EEDQ) [46, 471 did meet our requirements. 
This compound is known to react with 
carboxylic acid groups with the formation 
of mixed carbonic anhydrides (Scheme 2). 
However, we observed that these mixed 
anhydrides disproportionate into symmetrical 
acid anhydrides. Thus, addition of EEDQ 
to a solution of PGA in dimethylformamide 
gave rise to a solid transparent gel within 
30 min due to the formation of acid an- 
hydride crosslinks. These crosslinks are 
hydrolysed by water, which ultimately 
results in redissolution of the gels. In the 
presence of equimolar amounts of adria- 
mycin, these gels are not formed. This obser- 
vation provides additional chemical evidence 
for the formation of both symmetrical 
acid anhydrides and the amides anticipated. 
A slight excess of EEDQ in the reaction 
mixture also gave rise to the formation 
of transparent gels after 24 h at which time 
virtually all of the drug has been incorporated 
into the polymer. However, the crosslinks 
present in these gels are much more resistant 
towards hydrolysis than those of the acid 
anhydride type. It was concluded, that these 
crosslinks were, at least partly, of an ester- 
type nature. It was found that these ester 
bonds are selectively hydrolysed in the 
course of 2-3 days in the presence of imi- 
dazole. The hydrolysed material readily 
passed a 0.45 pm Millipore filter and the 
conjugate was purified and isolated by di- 
alysis, ultrafiltration, chromatography and 
lyophylization. The UV spectrum and the 
molar extinction were essentially the same 
as those of the free drug. Both the pure 
conjugates and mixtures with the free drug 
did follow Lambert Beer’s law. These find- 
ings enabled accurate measurements of 
the bound drug in the conjugate. In a high 
frequency NMR spectrum (500 MHz) both 
the C’ B-methyl doublet of the daunosamine 
moiety and the Me0 singlet (aglyconic por- 
tion) were discernible. 
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TABLE 2 
Covalently bound prodrugsa of adriamycin (ADR) derived from poly(arglutamic acid) (PGA)/oligopeptide grafts 
Batch of PGA Spacer 
(Table 1) 
Spacer load ADR load Yield of oligo- Yield of ADR- 
(mol%) (mol%) (wt%) peptide graft prodrug 
(by wt%) (by wt%) 
PGA, none 
PGA, none 
PGA, Gly-Leu 
PGA, Gly-Gly-Leu 
PGA, Gfy--Gly-Leu 
PGA, Gly-Gly-Leu 
PGA, Gly-Gly-Leu 
PGA, (Gly )-( Gfy-Gly-Leu) 
PGA, (Gly-Tyr)-(Gly-Leu)e 
PGA, (Gly-Tyr)-(Gly-Gly-Leu)e 
PGA, (Gly-Tyr)-(Gly-Gly-Leu)e 
100 
76 
91 
91 
95 
W/6’fd 
77C/34d 
lOOC/53d 
100C/67d 
6 16 - 96 
5 15 - 84 
4.2 6.6 85 58 
4 7 N.D.b N.D.b 
10 12 91 77 
8.3 11 92 83 
- 77 - 
10 13 60Cf93d 89 
3.6 5.0 90 82 
9.1 9.1 73 92 
3.3 3.3 40 56 
aSodium salt. 
bNot determined. 
CFirst spacer fragment. 
d Second spacer fragment, 
Wascade coupling of respective spacers (see Experimental). 
Results are given in Table 2. In early 
preparations we were faced with difficulties 
in removing small amounts of free (extracta- 
ble) drug from the conjugates. These mounts 
seemed to be bound to the conjugate by 
relatively stable charge transfer complexes 
(adriamycin itself exists as dimers in solu- 
tion 132, 331). By analogy with relatively 
stable anthracycline-DNA complexes [ 1, 
53, the surprising stability of the present 
conjugate-free drug complexes can be ex- 
plained by the additional formation of 
ion pairs (COO-, NH:). Both the presence 
of covalently bound drug and free car- 
boxylic acid groups are required for the 
formation of these complexes. Addition of 
the free drug to PGA led to the formation 
of a voluminous precipitate. Thus, apart 
from being a prodrug, the conjugate itself 
may also serve as a carrier for the free drug. 
These conjugate complexes are readily pre- 
pared either by (a) the mere addition of 
TABLE 3 
Complexes of adriamyein (ADR) and conjugates of adriamycin derived from PGA and PGA-oligopeptide 
graft (Table 2) 
Conjugate Covalently bound ADR Complex bound ADR Yield of complex 
(mol%) (wt%) (mol%) (wt%) (by wt%) 
PGA,-ADR 6 16 3.3 8.8 51a 
PGA,-ADR 5 15 3.3 9.3 93 
PGA,--Gly--Gly-Leu-ADR 4 7 2.9 4.4 89 
aLow yield due to gel formation of conjugate. 
the free drug to the conjugate or (b) by 
directly coupling adriamycin to PGA using 
0,5--0,6 equimolar amounts of EEDQ with 
respect to the free drug. In contrast to aque- 
ous solutions of adriamycin hydrochloride, 
these conjugate complexes were stable at 
physiological pH for long periods of time. 
Results are given in Table 3. 
In our approach to interpolate oiigopeptide 
spacers between the carrier and the drug, 
we preferred a different synthetic strategy 
than Trouet et al. [lo] on the following 
considerations: Firstly, in view of the ex- 
pense of the drug, a route which allows 
coupling of adriamycin in the very last step 
of the synthesis is more attractive than 
being engaged in a tedious multistep syn- 
thesis in which considerable amounts of 
the anthracycline are lost. Secondly, the 
preparation of carriers, which already con- 
tain the spacer arms desired will, eventually, 
be attractive for use in applications with 
other drugs, In the present approach, we 
preferred the use of commercially available 
C-unprotected ofigopeptides. To discriminate 
between the carboxylic groups of PGA 
and those of the oligopeptides introduced, 
preactivation of PGA prior to addition of 
the oligopeptide is essential. 
As mentioned above, the preactivation 
of lateral carboxylic acid groups in PGA 
by CD1 proved to be successful, but gave 
rise to extensive fragmentation of the peptide 
chain. By analogy with other methods of 
pr~a~tivat~on~ a number of additives were 
tried. Saccharin (2,3-dihydro-1,2-b~n~isoth~a- 
zole-3-on-l,l-dioxide) proved to be very 
successful. Saccharin imides [48] have 
been advocated for use in peptide synthesis 
but the method has gained little interest, 
probably due to difficulties in their prepara- 
tion (i.e. formation of DCC-saccharin ad- 
ducts or the use of highly reactive chemicals 
such as thionyl chloride) f483. We have 
found that the addition of CD1 to a solution 
containing both the carboxylic component 
and a slight excess of saccharin resulted in 
Lhe smooth generation of these imides in 
essentially quantitative yield and with only 
slight concomitant fragmentation of the 
pofypeptide chain. Moreover, these poly- 
meric imides proved to be sufficiently reac- 
tive to condense in high yields with the 
tetramethylguanidinium salts of the oligo- 
peptides of choice in DMF. The chemistry 
of the method is depicted in Scheme 3, 
and results are given in Table 2. Both sac- 
charin and imidazole, being the sole nan- 
toxic and water-soluble byproducts of the 
reaction, were readily removed by dialysis 
and molecular filtration, whereas the tetra- 
methyl guanidinium ions (‘H-NMR (D,O) 
6 3.0 ppm) were exchanged quantitatively 
by sodium ions using ion-exchange chro- 
matography. Theoretically, a partial transfer 
of the saccharinic imides from PGA to the 
carboxyl groups of the spacer may result 
in products in which some of these spacers 
are dimeric on the PGA-backbone and some 
of the PGA carboxyl groups are unreacted, 
Scheme 3. Grafting of PGA with Gly-43ly-Leu 
tripeptide using the CDI--saccharin method. 
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Pdy giutmic acid 
PGA) 
Saccharin 
PGA-peptlde-1 
NEM*CI- 
pcptidr-2 
TMG’-salt 
1 PGA- peptidv 
Saccharm 
-I 
PGA-pcplidc-1-poptide- 
Scheme 4. Stepwise elongation (cascade technique) 
of oligopeptide spacers with the use of phenyl di- 
chlorophosphate (PDCP). 
However, such an imide transfer has not 
been observed in fragment condensations 
in which C-unprotected substrates were 
used [48]. The simplicity of the present 
method also prompted us to investigate the 
possibility of stepwise elongation of the 
peptide spacer arms without the isolation 
of intermediate products. This was ac- 
complished readily with the use of phenyl 
dichlorophosphate [49] (PDCP) in DMF. 
The latter compound smoothly reacts with 
imidazole already present in the reaction 
mixture, thereby generating the correspond- 
ing phosphor-y1 diimidazolides, which in 
turn reactivate the C-terminal of the spacer 
arms giving the saccharin imides anticipated. 
The chemistry of the cascade coupling meth- 
od is depicted in Schemes 3 and 4. Oligo- 
peptide spacer arms containing up to 5 
amino acid residues (Gly-Tyr--Gly--Gly- 
Leu) were readily prepared by this method 
(Table 2) using Gly-Tyr and Gly-Gly- 
Leu in the CDI-saccharin and PDCP cascade 
methods, respectively. Degrees of incorpora- 
tion of both oligopeptide fragments were 
obtained from the proton integrals attributa- 
ble to appropriate isolated signals in the ‘H- 
NMR spectra (e.g. Tyr-Ar-H and Leu-CH, 
vs. Gly-fl-CH2 and total of all integrals, Fig. 
1). However, in one experiment (Table 2) 
in which the first spacer fragment (Gly- 
Tyr) was coupled in 77 mole percent, a 
part of the second spacer fragment (Gly- 
Leu) may be coupled directly to the car- 
boxylic groups which are left unreacted in 
the first coupling step. A slight modifica- 
tion of the method was necessary using 
glycine. The latter amino acid was applied 
using the corresponding t-butyl ester, rather 
than its TMG salt. The protecting group was 
removed quantitatively with the use of tri- 
fluoroacetic acid. The grafted polymers 
were isolated either as the sodium or as the 
pyridinium salts. In contrast to PGA, the 
free acids of these polymers were sticky 
gums which were difficult to handle. 
Finally, adriamycin was coupled to the 
grafted polymers (pyridinium salts) with 
the use of EEDQ, and isolated, purified 
and analysed for the drug as described for 
PGA with slight modifications. Results 
are given in Table 2. 
In contrast to the conjugates in which 
the drug was attached directly onto the 
carrier, the prodrugs in which peptide spacers 
were interpolated between the PGA back- 
bone and the drug (Fig. 2) readily yielded 
free adriamycin upon digestion with a rela- 
tively aspecific protease like papain. 
The voluminous coloured conjugates were 
stable at -20°C over prolonged periods 
of time. However, the batches derived from --_ 
high molecular weight PGA (1M, 200,000) 
had a tendency to age, resulting in slow or 
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6 7 6 5 4 3 2 1 0 
12 :, 
1 
HI 
2 
+JLA._- 
1 
6 
7 a, I,, , 
6 7 6 5 4 -3 2 1 0 
I--,----/ 
Fig. 1. Interrelated ‘H-NMR (80 MHz, D,O) spectra and assignments of Gly-Gly-Leu, and the polypeptide grafts 
PGA-Gly-Gly - Leu and PGA-Gly-Tyr-Gly-Gly-Leu, respectively. 
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Lysosomal attack 
’ wj 
GJU L Gly -Gly-L-Leu ‘Adriamycin 
Fig. 2. Monomeric unit in protease-activated macro- 
molecular prodrug of adriamycin. 
even poor solubility in water and the re- 
formation of microgel particles. The branched 
conjugates also had a tendency to give charge 
transfer complexes with free adriamycin 
(Table 3), albeit not with the extreme stabil- 
ity as was found for the conjugates not con- 
taining the spacer arms. Surprisingly, these 
complexes were more stable upon storage 
and did redissolve more readily than the 
conjugates from which they were prepared. 
Thus, apart from being interesting devices 
both in terms of controlled extracellular 
release of the (complexed) drug and endocel- 
lular release of the (covalently bound) drug, 
the present complexes are stable formula- 
tions at physiological pH for both the pro- 
drug and free adriamycin. 
MATERIALS AND METHODS 
Tetrahydrofuran (NCA preparation) was 
stirred with finely powdered potassium 
hydroxide (10 g/l), filtered and distilled 
from calcium hydride under a nitrogen 
atmosphere. Toluene used for the polymeri- 
zation of NCA was dried azeotropically. 
Pyridine (1 1) was distilled from chloro- 
sulphonic acid (10 ml) and distilled. Di- 
methylformamide (spectrograde) was pur- 
chased from Janssen (Belgium). All chemicals 
used, including oligopeptides (Pierce Chem. 
Comp.) are commercially available. Small- 
scale reactions were conducted in Reacti 
vials (Pierce Chem. Comp.). ‘H-NMR spectra 
(internal Me$i (CDCl,, DMSO d6) or sodium 
2,2-dimethyl-2-silapentane-5sulfonate ’ 
DzO) were recorded with Bruker WP s’i 
(80 MHz) and Bruker WM 500 (500 MHz) 
spectrometers. TLC was performed on silica 
gel (Merck Kieselgel 60 F254) using n-buta- 
nol-acetic acid-water (4: 1: 1) as the eluent. 
Spots were visualised with ninhydrin spray 
and/or UV light (245 nm). Immersible mo- 
lecular filters (CX-lo), filters (HA 0.45 pm) 
and a stirred pressured cell (Xx42.04710) 
were purchased from Millipore Benelux, 
Belgium. 
Polybglutamic acid) 
Glutamic acid 5-benzylester [ 371 N- 
carboxyanhydride [38] (10 g, 38 mmol, 
m.p. 92-93.5%) was polymerized in toluene 
(1 1) under a blanketing atmosphere (N,, 
room temperature, 5 days) using triethyl- 
amine (200 ~1, 1.44 mmol) as the initiator. 
Then, a brisk stream of hydrogen bromide 
was passed through the reaction mixture 
under vigorous stirring (20 min) and the 
mixture was allowed to stand overnight. 
The toluene was decanted and the poly- 
acid was washed with portions (100 ml) 
of fresh toluene (2X ) and acetone (5X ) 
until the washings were colorless. 
The crude polyacid was stirred in sodi- 
um phosphate buffer (100 mM, 100 ml, 
pH 7) and aqueous sodium bicarbonate 
solution was added dropwise with stirring 
until a clear neutral solution resulted, which 
was dialyzed exhaustively against deionized 
water (Visking dialysis tubes g-36/32 in, 
internal stirring with a slow stream of nitro- 
gen), and filtered (Millipore 0.45 pm) with 
the aid of a stirred pressure cell (Millipore 
Xx42.04710). The filtered solution was 
acidified (HCl, pH 2), stirred (40°C 20 
min), and the precipitate was collected 
and washed with water. The fibrous wet 
mass was freeze dried (the air-dried com- 
pound dissolves less readily in dimethyl- 
formamide); yield was 3-4 g. ‘H-NMR 
310 
and UV (sodium salt) spectra were in- 
distinguishable from those reported [ 391. 
Residual benzyl groups varied up to 5% 
(molar) as shown by UV measurements 
(250 nm, using L-glutamic acid 5-benzyl 
ester as the reference compound). Mo- 
lecular weights of these polymers were 
determined by their intrinsic viscosity at 25°C 
in 0.2 M NaCl solution [50-521 by [n] 
(dl/g) = 3.13 X lo3 (ii;[v)o.965; Table 1. 
Poly c+Lglutamic acid anhydride cross-linked gel 
Polyglutamic acid (50 mg, 0.39 mmol) 
was dissolved in dimethylformamide (1.34 
ml). Then, EEDQ (8.7 mg, 0.0352 mmol; 
0.09 eq) was added with stirring. Viscosity 
drops rapidly in the course of 2-3 min, 
and then gradually increases. Stirring is 
virtually impossible after 20 min, whereas 
after 45 min a solid rubbery gel results, 
indicating the formation of interchain sym- 
metrical acid anhydrides. The fragmentated 
gel dissolves completely in the course of a 
few hours in an aqueous solution of sodium 
bicarbonate, and even more rapidly in the 
presence of imidazole (1 M). The formation 
of a gel, however, does not occur in the 
presence of a relatively strong amine such 
as adriamycin (>0.04 mmol), which provides 
additional chemical evidence for the genera- 
tion of corresponding amides. The presence 
of a relatively weak amine, such as prazozine, 
does not hamper the formation of rubbery 
cross-linked gels. 
Copolymer of L-glutamic acid and 3’-N-(5-L-glu- 
taminyl) adriamycin 
Polyglutamic acid (200 mg, 1.55 meq) 
was dissolved in dimethylformamide (2-5 
ml, depending on the molecular weight of 
the polymer). The viscosity must be such 
that mechanical manipulation and stirring 
in a small reaction vial is possible. Free 
adriamycin was generated in a separate 
reaction vial from its hydrochloric acid salt 
(54 mg, 0.093 mmol) in dimethylformamide 
(2 ml) containing N-ethyl morpholine (20 ~1, 
0.16 mmol), and subsequently transferred 
to the polymer solution. Additional dimethyl- 
formamide (200 ~1) may be necessary to 
transfer virtually all of the adriamycin. 
The resultant solution was stirred for 3 h, 
EEDQ (26 mg, 0.11 mmol) was added, and 
the solution was stirred overnight. In prepara- 
tions when using high molecular weight 
polyacid or larger excesses of EEDQ a trans- 
lucent solid red gel containing cross-links 
of both the acid anhydride and 14-ester 
types may result. The solution or the gel, 
which was fragmentated mechanically, was 
stirred into a phosphate buffer (80 ml, 
100 mM, pH 7) solution containing imidazole 
(1 g) and the mixture was kept in the dark 
at 6°C for 3-5 days with occasional shak- 
ing. A diluted sample from the bulk gave 
the same UV spectrum and molar extinc- 
tion coefficient for bound adriamycin (E490 = 
84900 1 mol-’ cm-‘) as found for the free 
drug. The clear red solution was dialyzed 
against deionized water, freed from minute 
amounts of microgel particles (Millipore 
HA filter 0.45 pm), concentrated and washed 
by molecular filtration (Millipore immersible 
filters CX-10). TLC analysis may reveal 
small amounts of free adriamycin bound to 
the polymer by R-complexes. The conjugate 
can be purified by passing slowly the solution 
through an ion exchange column (100 X 4 
cm, Dowex HCRW-2, sodium form). Final- 
ly, the pure conjugate is isolated by con- 
centration (molecular filtration) to a small 
volume and lyophilization giving a brick- 
red voluminous mass; yield: 80-90% (re- 
covery, by weight), 90-100% (conversion 
to bound adriamycin; UV). 
Attempt to digest the copolymer (5 mg) 
with papain (5 mg) in phosphate buffer 
(pH 5.4) did not yield free adriamycin (TLC). 
In a 500 MHz (DzO) ‘H-NMR spectrum 
a small sharp singlet on the positive slope 
of the HOD resonance attributable to MeO- 
CH3 (aglycone; 6 3.99 ppm) and a doublet 
(daunosamine; C’G-CH3, 6 1.164, Jf5,16, .35 
Hz) were discernable). Other resonances were 
obscured by the resonances of polyglutamic 
acid, Table 2. 
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Complex of driamycin and the copolymer of L- 
giutamic acid and 3’-/V-(5.Lqlutaminyl) adriamycin 
Method a 
The copolymer above (210 mg) was dis- 
solved in water (10 ml) and the solution 
was transferred to a small flask fitted with 
a screw cap holding a molecular filter (Milli- 
pore immersible filter CX-10) attached to 
a vacuum line, a magnetic stirring bar and 
a septum outlet. Solutions were then in- 
troduced into the stirred cell with the aid 
of a syringe at a very slow rate which was 
controlled by the efflux from the stirred 
cell. In this manner a solution of adriamycin 
hydrochloride (40 mg, 0.069 mmol), water 
(5 ml), phosphate buffer (2 ml, 100 mM, 
pH 7) and water (250 ml), respectively, 
were introduced. No adriamycin was. present 
in the filtrate of the cell, indicating that 
all of the drug added is accomodated by 
the polymer in the form of ll-complexes. 
The solution of the macromolecular com- 
plex was filtered (Millipore HA 0.45 pm) 
with the aid of a stirred pressure cell to re- 
move any microgel particles, and the filtrate 
and washings were again concentrated to a 
small volume with the aid of an immersible 
molecular filter as described above. The 
polymeric drug was finally isolated by lyo- 
phylization (240 mg,, 95%). The material 
behaved as one entity in dialysis, molecular 
filtration and gel chromatography (Sephadex 
GlO), but was readily decomposed into 
the conjugate and free adriamycin by ion- 
exchange chromatography (polystyrene, sul- 
phonate type, sodium form) and TLC. The 
UV spectrum of the polymeric complex 
was virtually the same as that of adriamycin 
or its conjugate, Table 3. 
Method b (incomplete covalent linkage of the drug 
onto ~lyglutamic acid) 
Polyglutamic acid (ZOO mg, 1.55 mmol) 
was dissolved in dimethylformamide (1 ml) 
and a suspension of adriamycin, generated 
from its hydrochloric acid salt (108 mg, 
0.186 mmol), N-ethyl morpholine (25 ~1) 
in dimethylformamide (4 ml) was added. 
The solution was stirred for an hour, EEDQ 
(25 mg, 0.093 mmol) was added, and stirring 
was continued overnight. The contents of 
the vial were dissolved in phosphate buffer 
(100 ml, 100 ti, pH 7.0) and the solution 
was dialysed exhaustively with internal 
stirring by a slow stream of nitrogen. The 
solution was passed through a ~~lipore 
filter (HA 0.45 pm) and prior to lyophyliza- 
tion the filtrate was concentrated by mo- 
lecular filtration as described in Method a. 
The material prepared was indistinguishable 
from that prepared according to Method a. 
Polyglutamic acid glycylglycyl-L-leucine graft (PGA- 
Gly-Gly-L-Leu), using N,/V’.-carbonyl diimidazole 
(CD11 1441 as the sole condensing agent 
Polyglutamic acid (33 mg, 0.25 mmol) 
was dissolved in dimethylformamide (1 ml); 
CD1 (60 mg, 0.35 mmol) was added and 
the solution was stirred under rigid exclu- 
sion from moisture. The reaction between 
the two components was accompanied with 
the evolution of carbon dioxide and with 
a dramatic decrease in the viscosity of the 
solution. Then, a solution of Gly-Gly-L- 
Leu N,N,N’,N’-tetramethyl guanidinium salt 
(TMG’, prepared by the slow addition of 
~,~,~‘,~‘-te~~ethyl guanidine (TMG; 30 
~1, 0.25 mmol) to a stirred suspension of 
finely powdered Gly-Gly-It-Leu in di- 
methylformamide (4 ml)) was added. Stirring 
was continued for three days. The solution 
was taken in phosphate buffer (15 ml; 100 
m&f, pH 7.0), the resultant solution was 
dialysed against water, concentrated by 
molecular filtration and freeze dried. Yields 
turned out to be irreproducible (5-48%), 
and degrees of substitution erratic (up to 
15%, molar). The low yields and poor results 
are without any doubt attributable to ex- 
tensive self-fragmentation of the polyacid 
imidazoles and contrast with coupling ex- 
periments in which saccharin is used as an 
additive. 
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Polyglutamic acid oligopeptide graft, using saccharin 
as a CDLadditive (general procedure, Scheme 3) 
Polyglutamic acid (129 mg, 1 mmol eq) 
and saccharin (220 mg, 1.2 mmol) were 
dissolved in dimethylformamide (1-4 ml, 
depending on the molecular weight of the 
polymer). In a separate vial, N,N,N’,N’-tetra- 
methylguanidine (TMG, 131 ~1, 1.05 mmol) 
was slowly added to a stirred suspension of 
the finely powdered amino acid or oligo- 
peptide (1 mmol) selected. After all solids 
have gone into solution, N,N’-carbonyl 
diimidazole (227 mg, 1.4 mmol) was added 
to the solution containing both the polymer 
and additive to generate the polymeric 
saccharinic acid imides (30 min stirring). 
To this solution was added the solution 
containing the TMG salts of the oligopep- 
tide and the resulting reaction mixture 
was stirred for 3 days. The solution was added 
to a phosphate buffer (25 ml, 250 r&f, 
pH 7.0) and the resultant solution was dia- 
lysed against water, filtered (Millipore HA 
0.45 km) with the aid of a stirred pressure 
cell, concentrated by molecular filtration, 
and freeze dried. A lo-20 mg sample of 
the product was dissolved in a small volume 
of deuterium oxide and freeze dried prior 
to ‘H-NMR analysis. The ‘H-NMR spectra 
of the products were in accordance with 
the structures assigned. Degrees of substitu- 
tion were calculated from proton integrals 
attributable to structure elements in spacer 
(e.g. leucine-CH3) and backbone. See Table 
2 and Fig. 1. 
Polyglutamic acid glycine graft 
Polymeric saccharin imides were generated 
from polyglutamic acid (129 mg, 1 mmol 
eq) as described above. A solution of glycine 
t-butyl ester hydrochloride (170 mg, 1.05 
mmol) and TMG (131 ~1, 1.05 mmol) in 
dimethylformamide (2 ml) was added, and 
the reaction mixture was stirred for 3 days. 
The clear solution was diluted with dimethyl- 
formamide (10 ml) and then added dropwise 
to a vigorously stirred aqueous phosphate 
buffer (600 ml, 100 miV, pH 7.0). Fibrous 
polyglutamic acid glycine t-butyl ester graft 
precipitates in essentially quantitative yield. 
The material was washed with water and 
dried in uacuo. A ‘H-NMR spectrum (DMSO 
d6) was in accordance with the structure 
assigned: d 1.35 (s, 9H, t-Bu); 1.7-2.5 
(mm, 4H, Glu-CH,); 3.7-4.0 (complex 
multiplet indicating prochirality of Gly- 
CH? introduced by the polymer, 2 H); 4.2- 
4.5 (m, lH, Glu-CH). Degrees of substi- 
tion (up to 95%, molar) were obtained 
from the ratios of the Glu-CH2 and t-Bu- 
CHB proton integrals. 
The protected polymer was dissolved in 
trifluoroacetic acid (3 ml) and stirred (3 
min) and rapidly concentrated in vacua 
(2O”C, bath). The solid mass obtained was 
dissolved in aqueous phosphate buffer (250 
mM, pH 7.0,lO ml), and the pH of the result- 
ing suspension was readjusted to pH 7.0 by 
the portionwise addition of sodium carbonate 
and stirring. The clear solution obtained 
was further processed, purified and sub- 
jected to analysis as described for the poly- 
glutamic acid oligopeptide grafts described 
above. 
Polyglutamic acid oligopeptide graft using a two-step 
cascade coupling procedure without isolation of 
intermediate coupling products 
Polymeric saccharin imides derived from 
polyglutamic acid (1 mmol eq), NJ’-car- 
bony1 diimidazole and saccharin were gener- 
ated as described above and allowed to 
react with an oligopeptide (1.05 mmol eq) 
TMG salt in dimethylformamide solution. 
After incorporation of the oligopeptide of 
choice (3 days), the C-terminal groups of 
the spacer arms present can be reactivated 
by the addition of N-ethyl morpholine (152 
~1) and a freshly prepared (<15 s) solution 
of phenyl dichlorophosphate [49] (180 ~1) 
in dimethyl formamide (0.5 ml), respective- 
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ly (Scheme 4). The resulting light yellow 
solution was stirred for 4 h, and the second 
oligopeptide of choice (1.05 mmol) acid and 
TMG (132 ~1) in dimethylformamide (2 ml) 
was added. The solution was then stirred 
for 3 days. The polymers containing the 
elongated oligopeptide grafts (up to 5 amino 
acid residues) were isolated, purified and 
subjected to analysis as described above. 
Degrees of substitution of the oligopeptide 
fragments were obtained from the proton 
integrals attributable to appropriate isolated 
signals in the ‘H-NMR spectra (e.g. Tyr- 
Ar-H and Leu-CH, vs. Glu-CH, and total of 
all integrals). Results are given in Table 2 
and Fig. 1. 
Polyglutamic acid oligopeptide graft adriamycin 
conjugates (general procedure) 
Polyglutamic acid oligopeptide graft sodi- 
um salt (1 mmol eq) was dissolved in a 
small amount of water and slowly passed 
through an ion-exchange column (poly- 
styrene sulphonate type, pyridinium form, 
prepared by neutralization of the acid form 
by pyridine, and washing with distilled 
water). The pyridinium form of the poly- 
peptide was collected and freeze dried. 
The voluminous mass was dissolved in a 
minimum amount of dimethylformamide 
(magnetic stirring of the viscous solution 
should be possible). Then, N-ethylmorpholine 
(0.1 mmol eq) and adriamycin hydrochloric 
acid salt (0.1 mmol eq) are added. After 
dissolution of all solids, EEDQ (0.11 mmol 
eq) was added. The extent of incorporation 
of the drug can be monitored by TLC analysis 
(a minute sample is taken in phosphate buf- 
fer (50 ~1) and subjected to two-dimensional 
TLC analysis (same solvent), to account for 
artefacts caused by the presence of dimethyl- 
formamide and salts present). In some experi- 
ments the addition of more N-ethylmorpho- 
line and EEDQ may improve the coupling 
yield of adriamycin. The reaction mixture 
was stirred for an additional 24 h, then 
added to phosphate buffer, and further 
processed, isolated and analyzed for covalent- 
ly bound adriamycin (UV) as described for 
the copolymer of L-glutamic acid and 3’- 
N-(5-L-glutaminyl) adriamycin. All com- 
pounds are believed to be microheterogeneous 
with respect to molecular weight, degree of 
substitution of both spacer and drug, but 
all behave as one entity in dialysis, chro- 
matography and ultrafiltration. All com- 
pounds were sterilized by filtration (Milli- 
pore HA 0.45 pm), and should be stored in 
the dark in a freezing chest. Frozen solutions 
are more resistant to ageing than the solid 
compounds. Results are given in Table 2. 
Incubation of the PGA-Gly-Gly-Leu 
(5 mg) with papain (5 mg) in phosphate buf- 
fer (pH 5.4) gave rise to the formation of 
adriamycin (TLC) within 5 min. 
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